ArticleFrontiers in immunology2016
Minimal Residual Disease Detection and Evolved
Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing.Cancer cell international · 2024Article
- Self-supervised learning of T cell receptor sequences exposes core properties for T cell membership.Science advances · 2024Article
- Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia.Haematologica · 2023Article
- Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.Haematologica · 2022Article
- The Diagnostic and Prognostic Potential of the B-Cell Repertoire in Membranous Nephropathy.Frontiers in immunology · 2021Article
- Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation.Blood research · 2020Review
- Acute lymphoblastic leukemia clonal distribution between bone marrow and peripheral blood.Pediatric blood & cancer · 2020Article
- Developing an Unbiased Multiplex PCR System to Enrich theFrontiers in immunology · 2020Article
- Next-Generation Sequencing in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2019Review
- Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.Journal of hematology & oncology · 2018Article
- A Comprehensive Analysis of the T and B Lymphocytes Repertoire Shaped by HIV Vaccines.Frontiers in immunology · 2018Article
- T Cell Receptor Profiling in Type 1 Diabetes.Current diabetes reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute B lymphoblastic leukemia (B-ALL) is one of the most common types of childhood cancer worldwide and chemotherapy is the main treatment approach. Despite good response rates to chemotherapy regiments, many patients eventually relapse and minimal residual disease (MRD) is the leading risk factor for relapse. The evolution of leukemic clones during disease development and treatment may have clinical significance. In this study, we performed immunoglobulin heavy chain (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.